Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | FLT1 | P17948 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | FLT4 | P35916 | 2/20 | 0.55 |
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.53 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260798 | 0.86 | EGFR (0.55) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL19260666 | 0.85 | TLR7 (0.59) | EHMT2EHMT1SPIN1DNMT1TLR7 | |
| SCHEMBL19260694 | 0.84 | SPIN1 (0.58) | EHMT2EHMT1SPIN1DNMT1TLR7 | |
| SCHEMBL20720727 | 0.84 | EHMT2 (0.54) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL20720714 | 0.82 | EHMT2 (0.61) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL20720733 | 0.80 | EHMT2 (0.59) | EHMT2EHMT1SPIN1DNMT1TLR7 | |
| SCHEMBL19260759 | 0.80 | EHMT2 (0.57) | FLT1KDRFLT4EHMT2EHMT1 | |
| SCHEMBL19260606 | 0.80 | EHMT2 (0.57) | EHMT2EHMT1SPIN1DNMT1TLR7 | |
| SCHEMBL6335566 | 0.80 | EGFR (0.60) | EGFRFLT1KDRFGFR1FLT4 | |
| Formic Acid SCHEMBL20720644 | 0.80 | EHMT2 (0.50) | EGFRFLT1KDRFGFR1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EGFR 4848/4885FLT1 4648/4885KDR 4539/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EGFR 4848/4885FLT1 4648/4885KDR 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.